In this report, levels of the 3243 A to G mtDNA mutation associated with the mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome were measured in different heteroplasmic tissues of subjects in a kindred including adults with variable clinical phenotypes and a fetus. The relative proportions of mutant mtDNA varied widely (0 03 to 067) between identical tissues of the six different subjects and between different tissues of the same subjects. In the one adult for whom sufficient data were available there was an apparent correlation between the distribution of mutant mtDNA and clinical presentation. A woman without neurological symptoms who died prematurely with a cardiomyopathy and lactic acidosis had higher proportions of mutant in heart (0-49, SD 0 02), skeletal muscle (0-56, SD 0 01), and liver (0 55, SD 0-12) than in other tissues studied (for example, kidney, 0 03, SD 0-01). A strikingly different result was found in a 24 week old fetus in whom there was little variation in heteroplasmy in different tissues (average proportion of mutant mtDNA in six tissues, 0-53, SD 0 02). These observations add cardiomyopathy to the growing list of presenting features of the 3243 mtDNA mutation. The unique results from the fetus suggest also that selection pressures acting on either wild type or 3243 mutant mtDNA (rather than variation from replicative segregation of the heteroplasmic mtDNA) may be responsible primarily for the variable levels of 3243 mutant mtDNA in different heteroplasmic tissues of adults. (J Med Genet 1994;31:41-44) The mitochondrial encephalomyopathies include several easily recognisable clinical syndromes,'-as well as a broad range of less well defined syndromes resulting from dysfunction of one or more systems of the body that rely primarily on oxidative phosphorylation for cellular energy production.7 Different mutations in mtDNA have been associated with many of these.4>'0
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MtDNA is found in multiple copies in each mitochondrion and thus in hundreds to thousands of copies per cell."-" All members of the kindred tested were heteroplasmic for the MELAS 3243 mutation. The proportion of mutant mtDNA varied from 0 03 to 0-67 between different subjects and different tissues (table) . Comparison of the proportion of mutant mtDNA in the same tissue showed differences between subjects, for example, for white blood cells the proportion of mutant mtDNA was 0 39 (SD 0 04) in III.5, 0 19 in III.3, and 0 22 (SD 0-04) in I1.1. In II.2 and III.5 there was large variation in the percentage of mutant mtDNA between different tissues. This was particularly striking in II.2, in whom the mutation was near the limit of detection in gut, spleen, and kidney (0 04), although present at significantly higher levels of between 0 49 and 0-56 in cardiac and skeletal muscle and liver (p<0 001) (fig 2) . A significant difference between the proportions of mutant in cardiac and skeletal muscle was also seen (p<0-02), although this was small (difference of means, 0 07).
In contrast to these results, in the fetus IV. 1 there was either no variation or only a small variation in the percentage of mutant between different tissues: maximum differences of 0 05 in the proportion of mutant mtDNA were found in comparisons of kidney and cultured fibroblasts or optic nerve (p < 0 01) (fig 2) . It is notable that extra-embryonic tissue (placenta) had a similar proportion of mutant to the several fetal tissues studied.
To determine whether growth in vitro results in a change in the relative proportions of mutant and wild type mtDNA in fibroblasts, a primary culture from IV. 1 was repeatedly split and regrown to confluence through approximately 14 [5]
[3] [7] [7]
[5] MELAS syndrome.8 It illustrates again that there is a range of clinical phenotypes associated with the 3243 mutation. Cardiomyopathy has been well described in association with MELAS (found, for example, in one of the first reported cases20), although we are not aware that it has been reported as the presenting feature of the 3243 mutation before. It may be relevant that the highest levels of mutant mtDNA were found in organs (heart, skeletal muscle, and liver) whose failure figured prominently in the fatal syndrome of cardiomyopathy and lactic acidosis and almost undetectable levels were found in other tissues studied.
The observation that levels of maternally inherited mutant mtDNA can vary over a broad range between different tissues in heteroplasmic subjects was unexpected2' given the estimated number of mitochondrial genomes in somatic cells (for example, from no fewer than 500 in fibroblasts to several thousand in myocytes)' 13 and zygotes (which may have as many as 100 000 mtDNA molecules).15 If such large numbers of mitochondrial genomes assorted independently, neutral drift theory would predict a relatively slow change in cytoplasmic genotype during somatic cell differentiation and tissue formation. 16 One possible explanation for the large variation seen in patients such as II.2, therefore, is that the number of independently segregating cytoplasmic units of heredity is much smaller than There is also a growing body of evidence that selection factors in tissues may cause the proportion of mutant mtDNA in a tissue to change with time as previously shown for mtDNA deletion mutations.22 First, it seems plausible that there is a relationship between the proportion of mutant mtDNA and mitochondrial dysfunction in any given tissue,2324 and clinical studies show that MELAS (which characteristically has onset after birth and normal early development)' 6 is a progressive disorder. Second, only a subset of the highly oxidative organ systems of the body are most commonly involved in the MELAS syndrome (notwithstanding less frequent pathology in other oxidative tissues, for example, heart). Third, there is a consistently greater proportion of mutant in muscle than in blood' and a trend towards relatively greater accumulation in muscle than in blood with age (J Poulton, unpublished observations). Finally, preferential accumulation of the 3243 mutant mtDNA to levels that lead to impairment of mitochondrial polypeptide synthesis has been shown in rho-0 cells repopulated with heteroplasmic mitochondria. 23 To our knowledge, this is the first report on the distribution of the 3243 mutation between fetal tissues. There has been only one previous report of any mutant mtDNA distribution in the fetus. 25 The contrast between the remarkable similarity in levels of 3243 mutant mtDNA in the broad range of different tissues from the fetus and the large differences seen between some adult tissues suggests to us that tissue specific selection factors affecting mitochondrial genotype are more important than linked segregation of multiple genomes in determining the pattern of tissue heteroplasmy in the adult. As the mechanism and strength of selection may vary for different disease associ- We thank Drs Bunting, Graham, and Gould for their generous assistance and support with clinical aspects of this study. We gratefully acknowledge useful discussion and criticism in preparation of the manuscript from Drs J Poulton and K Morten. Funding was provided by the Wellcome Foundation (GKB), MRC (Canada) and NIH (PMM).
